The L3MBTL2 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the L3MBTL2 gene in the human non-small cell lung cancer-derived NCI-H1975 cell line. This product comprises a heterogeneous pool of edited cells carrying disruptions in the L3MBTL2 locus, providing a robust loss-of-function model for functional genomics and chromatin biology studies. The polyclonal format avoids clonal selection biases, enabling investigation of the overall impact of L3MBTL2 ablation in a genetically diverse cellular context.
The host NCI-H1975 cell line is an adherent epithelial cell line derived from a human lung adenocarcinoma and harbors the activating EGFR L858R mutation. These cells serve as a widely utilized model for non-small cell lung cancer, particularly for studying EGFR signaling, drug sensitivity, and mechanisms of resistance. Their established use in cancer epigenetic research makes them an ideal background for interrogating the role of chromatin-associated proteins such as L3MBTL2.
L3MBTL2 is a transcriptional repressor and reader of methylated histone marks, specifically recognizing H3K27me and H4K20me through its MBT domains. It functions downstream of the histone methyltransferase EZH2, which establishes H3K27me marks, and integrates into a PRC1-like complex by interacting with core components RING1 and RYBP. Through these interactions, L3MBTL2 mediates chromatin compaction and represses transcription of key developmental regulators, including HOX gene clusters and potential tumor suppressor genes. The complex also associates with other Polycomb group proteins and histone modifications, thereby modulating gene expression programs central to differentiation and proliferation.
In the context of the NCI-H1975 lung adenocarcinoma model, L3MBTL2 knockout may relieve transcriptional repression at loci critical for growth control and lineage commitment, potentially altering cellular proliferation, differentiation, and response to EGFR-targeted therapies. Given the interplay between Polycomb-mediated silencing and oncogenic signaling, this model enables exploration of how histone methylation reading and chromatin organization contribute to lung cancer pathogenesis. The EGFR mutation background further provides a unique platform for assessing combinatorial effects of epigenetic dysregulation and kinase-driven oncogenesis.
This knockout model is well-suited for diverse experimental applications, including verification of L3MBTL2 protein depletion by western blotting, transcriptomic profiling via RNA-seq to identify de-repressed target genes, and chromatin immunoprecipitation (ChIP-qPCR) to assess histone methylation changes at specific loci. Functional studies such as cell proliferation and drug sensitivity assays, along with flow cytometry for differentiation markers, can elucidate the phenotypic consequences of L3MBTL2 loss. These polyclonal knockout cells facilitate robust, reproducible investigations in chromatin biology and cancer epigenetics. For further information or technical support, please contact Ascent Research.
